Pneuma Respiratory, which introduced a digital soft mist inhaler in November 2017, has announced the appointment of former Boehringer Ingelheim VP of Respiratory Products Steven Kesten as its new President and Chief Medical Officer. Since leaving Boehringer Ingelheim in 2010, Kesten has held VP and Chief Medical Officer positions at Uptake Medical and Cytori Therapeutics and worked as a consultant.
Kesten commented, “I am extremely excited about Pneuma’s innovative approach to improving the effectiveness of therapeutic agents that will help to address continuing issues in medication delivery in a large population of patients who continue to suffer from asthma and COPD. I believe that Pneuma’s inhaler technology can positively influence the large socioeconomic impact of obstructive lung disease. The fully digital and breath activated platform has the flexibility to include all classes of inhaled drugs and the potential to explore poorly met needs in other diseases.”
Pneuma’s Pneumahaler device is a breath-activated soft mist inhaler that uses Bluetooth technology and a mobile app, the company said.
Read the Pneuma Respiratory press release.
